β-丙内酯灭活的全病毒通用流感疫苗的安全性和免疫原性:一项随机、双盲、双模拟、安慰剂对照的1期临床试验。
完整摘要 · 中文译文
流感造成沉重的疾病负担,但现有疫苗对疫苗中未包含的毒株和亚型的保护广度有限。BPL-1357是一种全病毒灭活疫苗,含有四种野生型低致病性禽流感病毒,在动物模型中已证明对多种流感病毒具有显著的保护作用。在本项I期试验中,45名健康参与者被随机分配接受BPL-1357肌内注射(IM)、鼻内接种(IN)或安慰剂,采用初免和加强策略,间隔28天。主要终点包括从入组至加强免疫后28天期间的不良事件(AEs)和严重不良事件(SAEs)。次要终点为加强免疫后182天内的AEs和SAEs,以及针对血凝素和神经氨酸酶疫苗抗原的血清IgG和鼻黏膜IgA滴度测定。不良反应大多轻微,除IM组更常见轻度注射部位疼痛外,仅少数患者出现不良事件。与安慰剂相比,IM BPL-1357诱导了针对H3、H5和H7的更高血清IgG滴度,分别有71.4%、71.4%和85.7%的参与者出现应答。接种IM BPL-1357的参与者还出现了血清中和反应和NA特异性反应,但未出现针对HA或NA的黏膜IgA应答。IN接种后观察到细微的黏膜和血清反应,与临床前实验相似。这些结果提示BPL-1357耐受性良好且具有免疫原性,尤其是在IM接种时,但还需更多工作来评估其他剂量水平、进一 她的研究旨在表征诱导免疫,并评估其对流感感染和疾病的效力(NCT05027932)。
完整摘要 · 英文原文
Influenza inflicts substantial burden of disease, but current vaccines have limited breadth of protection against strains and subtypes not in the vaccine. BPL-1357, a whole-virus, inactivated vaccine containing four wild-type, low-pathogenicity avian influenza viruses has demonstrated remarkable protection in animal models against a wide range of influenza viruses. In this phase I trial, forty-five healthy participants were randomized to receive BPL-1357 intramuscularly (IM), intranasally (IN), or placebo, in a prime and boost strategy, 28-days apart. The primary endpoints consisted of adverse events (AEs) and serious adverse events (SAEs) from enrollment through 28 days after the boost. The secondary endpoints were AEs and SAEs through 182 days after the boost and measurement of serum IgG and nasal IgA titers against hemagglutinin and neuraminidase vaccine antigens. Adverse effects were mostly mild and, other than mild injection-site pain more frequently observed in the IM group, occurred in a minority of patients. IM BPL-1357 induced higher serum IgG titers against H3, H5, and H7 relative to placebo, with 71.4%, 71.4%, and 85.7% of participants demonstrating a response. IM BPL-1357 vaccinated participants also experienced serum neutralizing and NA-specific responses, but no mucosal IgA responses against HA or NA. Subtle mucosal and serum responses were observed after IN vaccination, similar to preclinical experiments. These results suggest that BPL-1357 is well tolerated and immunogenic, particularly when given IM, but more work is needed to assess other dose levels, further characterize induced immunity, and evaluate efficacy against influenza infection and disease (NCT05027932).